{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:04:50Z","timestamp":1784232290294,"version":"3.55.0"},"reference-count":265,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003329","name":"Ministry of Economy and Competitiveness","doi-asserted-by":"crossref","award":["PI18\/00207"],"award-info":[{"award-number":["PI18\/00207"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003329","name":"Ministry of Economy and Competitiveness","doi-asserted-by":"crossref","award":["PI15\/00558 and PI18\/00139"],"award-info":[{"award-number":["PI15\/00558 and PI18\/00139"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"crossref"}]},{"name":"la Fondation pour la Recherche sur Alzheimer"},{"DOI":"10.13039\/501100001961","name":"AXA Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001961","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondation partenariale Sorbonne Universit\u00e9"},{"name":"Fondation pour la Recherche sur Alzheimer"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.neuropharm.2020.108081","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T11:59:34Z","timestamp":1589198374000},"page":"108081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery"],"prefix":"10.1016","volume":"185","author":[{"given":"Harald","family":"Hampel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vergallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Caraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Claudio","family":"Cuello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Lemercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly Virecoulon","family":"Giudici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Baldacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"H\u00e4nisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Haberkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Broich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Nistic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Emanuele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Llavero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Zugaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Luc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Giacobini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Lista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108081_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/7039816","article-title":"Nutrition and AGE-ing: focusing on Alzheimer's disease","volume":"2017","author":"Abate","year":"2017","journal-title":"Oxid. Med. Cell. Longev"},{"key":"10.1016\/j.neuropharm.2020.108081_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13195-017-0320-4","article-title":"Rho GTPases as therapeutic targets in Alzheimer's disease","volume":"9","author":"Aguilar","year":"2017","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2020.108081_bib3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0b013e318207b1b9","article-title":"Report of the task force on designing clinical trials in early (predementia) AD","volume":"76","author":"Aisen","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108081_bib4","first-page":"365","article-title":"microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF)","volume":"3","author":"Alexandrov","year":"2012","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib5","author":"Alzforum"},{"key":"10.1016\/j.neuropharm.2020.108081_bib6","series-title":"Fifth International Geneva\/Springfield Symposium on Advances in Alzheimer Therapy","first-page":"18","article-title":"Long-term treatment with rivastigmine continue to provide benefits for up to one year","author":"Anand","year":"1998"},{"key":"10.1016\/j.neuropharm.2020.108081_bib7","first-page":"98","article-title":"Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders","volume":"3","author":"Andreasson","year":"2016","journal-title":"Alzheimer\u2019s Dement. Diagnosis, Assess. Dis. Monit."},{"key":"10.1016\/j.neuropharm.2020.108081_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1474-4422(17)30040-6","article-title":"Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial","volume":"16","author":"Andrieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/aje\/kwm116","article-title":"Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies","volume":"166","author":"Anstey","year":"2007","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib10","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/nn.4087","article-title":"Stress weakens prefrontal networks: molecular insults to higher cognition","volume":"18","author":"Arnsten","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2016.00243","article-title":"CB2 cannabinoid receptor as potential target against Alzheimer's disease","volume":"10","author":"Aso","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","article-title":"Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases","volume":"91","author":"Bacioglu","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2020.108081_bib13","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1007\/s12035-019-1531-4","article-title":"Potential diagnostic value of red blood cells \u03b1-synuclein heteroaggregates in Alzheimer's disease","volume":"56","author":"Baldacci","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/14789450.2017.1304217","article-title":"Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases","volume":"14","author":"Baldacci","year":"2017","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.neuropharm.2020.108081_bib15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jshs.2016.08.007","article-title":"Biomarker-guided classification scheme of neurodegenerative diseases","volume":"5","author":"Baldacci","year":"2016","journal-title":"J. Sport Health Sci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/14789450.2019.1628643","article-title":"The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development","volume":"16","author":"Baldacci","year":"2019","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.neuropharm.2020.108081_bib17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/14737159.2019.1627202","article-title":"A frontline defense against neurodegenerative diseases:the development of early disease detection methods","volume":"19","author":"Baldacci","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.neuropharm.2020.108081_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/archgenpsychiatry.2011.1481","article-title":"Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia","volume":"69","author":"Barnes","year":"2012","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108081_bib19","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108081_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/appi.ajp.2017.17040404","article-title":"Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer's dementia in individuals with previous depression","volume":"175","author":"Bartels","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108081_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142143","article-title":"Network physiology: how organ systems dynamically interact","volume":"10","author":"Bartsch","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.neuropharm.2020.108081_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nn.4502","article-title":"Network neuroscience","volume":"20","author":"Bassett","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib23","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nn.2801","article-title":"Neuronal activity regulates the regional vulnerability to amyloid-\u03b2 deposition","volume":"14","author":"Bero","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib24","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-170602","article-title":"Cerebrospinal fluid and plasma levels of inflammation differentially relate to CNS markers of Alzheimer's disease pathology and neuronal damage","volume":"62","author":"Bettcher","year":"2018","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib25","doi-asserted-by":"crossref","first-page":"10882","DOI":"10.1523\/JNEUROSCI.5334-10.2011","article-title":"Heritability of working memory brain activation","volume":"31","author":"Blokland","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib26","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1074\/jbc.AC118.007195","article-title":"Amyloid-\u03b2 oligomers have a profound detergent-like effect on lipid membrane bilayers, imaged by atomic force and electron microscopy","volume":"294","author":"Bode","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108081_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0378-1119(02)00426-2","article-title":"The role of Rho GTPases in disease development","volume":"286","author":"Boettner","year":"2002","journal-title":"Gene"},{"key":"10.1016\/j.neuropharm.2020.108081_bib28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s12035-014-8657-1","article-title":"Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview","volume":"50","author":"Brosseron","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.arr.2019.01.003","article-title":"Exploring the relationship between physical activity, beta-amyloid and tau: a narrative review","volume":"50","author":"Brown","year":"2019","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2020.108081_bib30","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/17425255.2014.952630","article-title":"Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance","volume":"10","author":"Bruhn","year":"2014","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.nbd.2017.04.007","article-title":"NF-L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration","volume":"104","author":"Brureau","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrneurol.2011.60","article-title":"Depression and risk of developing dementia","volume":"7","author":"Byers","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108081_bib33","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3233\/JAD-2009-1071","article-title":"Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice","volume":"17","author":"Cao","year":"2009","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib34","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.phrs.2018.02.007","article-title":"Neurobiological links between depression and AD: the role of TGF-\u03b21 signaling as a new pharmacological target","volume":"130","author":"Caraci","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2020.108081_bib35","doi-asserted-by":"crossref","first-page":"e1631","DOI":"10.4088\/JCP.15m10413","article-title":"Reduced regional cortical thickness rate of change in donepezil-treated subjects with suspected prodromal Alzheimer's disease","volume":"77","author":"Cavedo","year":"2016","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108081_bib36","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib37","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jalz.2019.03.006","article-title":"Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease","volume":"15","author":"Chiesa","year":"2019","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.neuropharm.2020.108081_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neurobiolaging.2019.12.017","article-title":"Association of brain network dynamics with plasma biomarkers in subjective memory complainers","volume":"88","author":"Chiesa","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2020.108081_bib39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/cells8030211","article-title":"Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo","volume":"8","author":"Christ","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2020.108081_bib40","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.neuron.2005.10.028","article-title":"Synaptic activity regulates interstitial fluid amyloid-\u03b2 levels in vivo","volume":"48","author":"Cirrito","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2020.108081_bib41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","article-title":"Alzheimer's disease: strategies for disease modification","volume":"9","author":"Citron","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.108081_bib42","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nrd3869","article-title":"Drug repositioning for Alzheimer's disease","volume":"11","author":"Corbett","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.108081_bib43","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tins.2007.06.011","article-title":"Exercise builds brain health: key roles of growth factor cascades and inflammation","volume":"30","author":"Cotman","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tips.2017.07.005","article-title":"Early and late CNS inflammation in Alzheimer's disease: two extremes of a continuum?","volume":"38","author":"Cuello","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib45","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jalz.2018.05.006","article-title":"The national institute on aging\u2014alzheimer\u2019s association framework on Alzheimer's disease: application to clinical trials","volume":"15","author":"Cummings","year":"2019","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib46","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","article-title":"Alzheimer's disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.neuropharm.2020.108081_bib47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","article-title":"Alzheimer's disease drug development pipeline: 2018","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"10.1016\/j.neuropharm.2020.108081_bib48","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jalz.2016.06.001","article-title":"Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort","volume":"12","author":"Dage","year":"2016","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tips.2016.10.013","article-title":"Cancer precision medicine: from cancer screening to drug selection and personalized immunotherapy","volume":"38","author":"Deng","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib50","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.0b013e31823efc6c","article-title":"MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults","volume":"78","author":"Dickerson","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108081_bib51","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jagp.2016.11.014","article-title":"History of bipolar disorder and the risk of dementia: a systematic review and meta-analysis","volume":"25","author":"Diniz","year":"2017","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108081_bib52","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.neuropharm.2012.08.018","article-title":"Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells","volume":"63","author":"Dragicevic","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108081_bib53","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fnins.2019.00220","article-title":"Genetic overlap between alzheimer's disease and bipolar disorder implicates the MARK2 and VAC14 genes","volume":"13","author":"Drange","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib54","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jalz.2014.10.003","article-title":"Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease","volume":"11","author":"Dubois","year":"2015","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.neuropharm.2020.108081_bib55","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","article-title":"Revising the definition of Alzheimer's disease: a new lexicon","volume":"9","author":"Dubois","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib56","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib57","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib58","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.3233\/JAD-179929","article-title":"Role of neuroinflammation in the trajectory of Alzheimer's disease and in vivo quantification using PET","volume":"64","author":"Edison","year":"2018","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib59","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0165-6147(94)90057-4","article-title":"Inflammatory mechanisms in Alzheimer's disease","volume":"15","author":"Eikelenboom","year":"1994","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib60","author":"European Medicines Agency"},{"key":"10.1016\/j.neuropharm.2020.108081_bib61","article-title":"An early and late peak in microglial activation in Alzheimer's disease trajectory","volume":"aww349","author":"Fan","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108081_bib62","series-title":"Annual Meeting of the American Geriatrics Society","first-page":"A15","article-title":"Metrifonate improves the cognitive deficits of Alzheimer's disease patients in a dose-related manner","author":"Farlow","year":"1998"},{"key":"10.1016\/j.neuropharm.2020.108081_bib63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neulet.2013.06.044","article-title":"Association between the ABCG2 C421A polymorphism and Alzheimer's disease","volume":"550","author":"Feh\u00e9r","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2020.108081_bib64","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41582-018-0032-9","article-title":"Sex differences in Alzheimer disease \u2014 the gateway to precision medicine","volume":"14","author":"Ferretti","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib65","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","article-title":"Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study","volume":"11","author":"Fiandaca","year":"2015","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib66","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1471-4159.2011.07507.x","article-title":"Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease","volume":"120","author":"Fisher","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2020.108081_bib67","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2174\/1567205013666160219112854","article-title":"Lithium, a therapy for AD: current evidence from clinical trials of neurodegenerative disorders","volume":"13","author":"Forlenza","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2020.108081_bib68","first-page":"483","article-title":"Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease","volume":"11","author":"Fossati","year":"2019","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib69","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/brain\/awy008","article-title":"Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease","volume":"141","author":"Franzmeier","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108081_bib70","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s00213-017-4664-z","article-title":"Co-modulation of an allosteric modulator of nicotinic receptor-cholinesterase inhibitor (galantamine) and a 5-HT4 receptor agonist (RS-67333): effect on scopolamine-induced memory deficit in the mouse","volume":"234","author":"Freret","year":"2017","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2020.108081_bib71","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108081_bib72","doi-asserted-by":"crossref","first-page":"S551","DOI":"10.3233\/JAD-141302","article-title":"Is cognitive training an effective treatment for preclinical and early Alzheimer's disease?","volume":"42","author":"Gates","year":"2014","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib73","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17512433.2018.1501555","article-title":"Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases","volume":"11","author":"Geerts","year":"2018","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00198","article-title":"Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology","volume":"6","author":"Geerts","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib75","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10928-013-9297-1","article-title":"Quantitative systems pharmacology as an extension of PK\/PD modeling in CNS research and development","volume":"40","author":"Geerts","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.neuropharm.2020.108081_bib76","first-page":"181","article-title":"Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer\u2019 disease","volume":"62","author":"Giacobini","year":"2002","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2020.108081_bib77","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00023210-200115020-00001","article-title":"Do cholinesterase inhibitors have disease-modifying effects in Alzheimer??s disease?","volume":"15","author":"Giacobini","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2020.108081_bib78","series-title":"Alzheimer Disease","first-page":"187","article-title":"Cholinesterase inhibitors do more than inhibit cholinesterase","author":"Giacobini","year":"1997"},{"key":"10.1016\/j.neuropharm.2020.108081_bib79","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrneurol.2013.223","article-title":"Alzheimer disease therapy\u2014moving from amyloid-\u03b2 to tau","volume":"9","author":"Giacobini","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib80","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1073\/pnas.0909969107","article-title":"Genetic control over the resting brain","volume":"107","author":"Glahn","year":"2010","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.neuropharm.2020.108081_bib81","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1096\/fj.201700731R","article-title":"Declining levels of functionally specialized synaptic proteins in plasma neuronal exosomes with progression of Alzheimer's disease","volume":"32","author":"Goetzl","year":"2018","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2020.108081_bib82","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1096\/fj.201600756R","article-title":"Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease","volume":"30","author":"Goetzl","year":"2016","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2020.108081_bib83","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ana.25172","article-title":"High complement levels in astrocyte-derived exosomes of Alzheimer disease","volume":"83","author":"Goetzl","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib84","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1096\/fj.201700149","article-title":"Altered cargo proteins of human plasma endothelial cell\u2013derived exosomes in atherosclerotic cerebrovascular disease","volume":"31","author":"Goetzl","year":"2017","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2020.108081_bib85","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3389\/fnins.2019.01112","article-title":"Glucagon-like peptide-1: a focus on neurodegenerative diseases","volume":"13","author":"Grieco","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib86","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2174\/1567205016666190517121140","article-title":"Biomarkers for Alzheimer's disease","volume":"16","author":"Guzman-Martinez","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2020.108081_bib87","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.05.001","article-title":"An overview of microRNAs","volume":"87","author":"Hammond","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuropharm.2020.108081_bib88","first-page":"P1519","article-title":"Full genomic analysis OF ANAVEX\u00ae2-73 phase 2A ALZHEIMER\u2019S disease study identifies biomarkers enabling targeted therapy and a precision medicine approach","volume":"14","author":"Hampel","year":"2018","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00310","article-title":"Biomarker-drug and liquid biopsy Co-development for disease staging and targeted therapy: cornerstones for Alzheimer's precision medicine and pharmacology","volume":"10","author":"Hampel","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib90","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3233\/JAD-190197","article-title":"Lithium as a treatment for Alzheimer's disease: the systems pharmacology perspective","volume":"69","author":"Hampel","year":"2019","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib91","doi-asserted-by":"crossref","first-page":"101662","DOI":"10.1016\/j.pneurobio.2019.101662","article-title":"Time for the systems-level integration of aging: resilience enhancing strategies to prevent Alzheimer's disease","volume":"181","author":"Hampel","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib92","doi-asserted-by":"crossref","first-page":"2","DOI":"10.14283\/jpad.2018.43","article-title":"Revisiting the cholinergic hypothesis in alzheimer's disease: emerging evidence from translational and clinical research","volume":"6","author":"Hampel","year":"2019","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib93","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib94","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.3233\/JAD-179932","article-title":"Revolution of alzheimer precision neurology. Passageway of systems biology and neurophysiology","volume":"64","author":"Hampel","year":"2018","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib95","doi-asserted-by":"crossref","first-page":"177","DOI":"10.31887\/DCNS.2019.21.2\/hhampel","article-title":"Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease","volume":"21","author":"Hampel","year":"2019","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib96","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.phrs.2018.02.014","article-title":"Precision pharmacology for Alzheimer's disease","volume":"130","author":"Hampel","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2020.108081_bib97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.yfrne.2018.06.001","article-title":"Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification","volume":"50","author":"Hampel","year":"2018","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-181121","article-title":"The alzheimer precision medicine initiative","volume":"68","author":"Hampel","year":"2019","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib99","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.neurobiolaging.2014.03.026","article-title":"Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease","volume":"35","author":"Hanzel","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2020.108081_bib100","doi-asserted-by":"crossref","first-page":"44272","DOI":"10.1038\/srep44272","article-title":"Mining outcome-relevant brain imaging genetic associations via three-way sparse canonical correlation analysis in alzheimer's disease","volume":"7","author":"Hao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108081_bib101","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.0000000000006745","article-title":"Translating the biology of aging into novel therapeutics for Alzheimer disease","volume":"92","author":"Hara","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108081_bib102","series-title":"Sixth International Stockholm\/Springfield Symposium Advances in Alzheimer Therapy","first-page":"81","article-title":"Induction, secretion and pharmacological regulation of beta-APP in animal model systems","author":"Haroutunian","year":"2000"},{"key":"10.1016\/j.neuropharm.2020.108081_bib103","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/clpt.2013.176","article-title":"Network-based approaches in drug discovery and early development","volume":"94","author":"Harrold","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108081_bib104","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00005072-199906000-00008","article-title":"Loss of proteins regulating synaptic plasticity in normal aging of the human brain and in alzheimer disease","volume":"58","author":"Hatanp\u00e4\u00e4","year":"1999","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib105","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER- mitochondrion interface regulate Ca2+ signaling and cell survival","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2020.108081_bib106","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.neurobiolaging.2018.12.008","article-title":"Diet and biomarkers of Alzheimer's disease: a systematic review and meta-analysis","volume":"76","author":"Hill","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2020.108081_bib107","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrn2298","article-title":"Be smart, exercise your heart: exercise effects on brain and cognition","volume":"9","author":"Hillman","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003016","article-title":"The association of depression with subsequent dementia diagnosis: a Swedish nationwide cohort study from 1964 to 2016","volume":"17","author":"Holmquist","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.neuropharm.2020.108081_bib109","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.neuropharm.2018.01.040","article-title":"Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models","volume":"136","author":"H\u00f6lscher","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108081_bib110","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s12603-017-0957-5","article-title":"Cognitive changes with omega-3 polyunsaturated fatty acids in non-demented older adults with low omega-3 index","volume":"21","author":"Hooper","year":"2017","journal-title":"J. Nutr. Health Aging"},{"key":"10.1016\/j.neuropharm.2020.108081_bib111","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.plefa.2003.12.011","article-title":"Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function","volume":"70","author":"Horrocks","year":"2004","journal-title":"Prostagl. Leukot. Essent. Fat. Acids"},{"key":"10.1016\/j.neuropharm.2020.108081_bib112","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/bioinformatics\/bts139","article-title":"MDWeb and MDMoby: an integrated web-based platform for molecular dynamics simulations","volume":"28","author":"Hospital","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neuropharm.2020.108081_bib113","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/JAD-2010-1203","article-title":"Altered distribution of RhoA in Alzheimer's disease and A\u03b2PP overexpressing mice","volume":"19","author":"Huesa","year":"2010","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib114","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/ddr.21222","article-title":"Computational approaches for drug discovery","volume":"75","author":"Hung","year":"2014","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.neuropharm.2020.108081_bib115","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.tips.2014.04.010","article-title":"Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome","volume":"35","author":"Iulita","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib116","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jalz.2016.05.001","article-title":"An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: relation to cognitive decline and longitudinal evaluation","volume":"12","author":"Iulita","year":"2016","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib117","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib118","first-page":"1","article-title":"A\/T\/N\u202f: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108081_bib119","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.cellbio.21.020604.150721","article-title":"Rho GTPASES: biochemistry and biology","volume":"21","author":"Jaffe","year":"2005","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib120","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1212\/WNL.0000000000006082","article-title":"CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease","volume":"91","author":"Janelidze","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108081_bib121","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma \u03b2-amyloid in Alzheimer's disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108081_bib122","series-title":"Fifth International Geneva\/Springfield Symposium on Advances in Alzheimer Therapy","first-page":"147","article-title":"Long-term Tacrine treatment slows the increase of theta power in the EEG of mild Alzheimer patients compared to untreated controlsNo Title","author":"Jelic","year":"1998"},{"key":"10.1016\/j.neuropharm.2020.108081_bib123","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jcpt.12808","article-title":"Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease","volume":"44","author":"Jojo","year":"2019","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108081_bib124","first-page":"1813","article-title":"The many roles of computation in drug discovery","volume":"303","author":"Jorgensen","year":"2004","journal-title":"Science 84"},{"key":"10.1016\/j.neuropharm.2020.108081_bib125","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00401-016-1552-2","article-title":"CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study","volume":"131","author":"Kang","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib126","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2020.108081_bib127","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2018.3459","article-title":"Association of cerebrospinal fluid neurofilament light protein with risk of mild cognitive impairment among individuals without cognitive impairment","volume":"76","author":"Kern","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neuropharm.2020.108081_bib128","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/ijms20071591","article-title":"Physical activity alleviates cognitive dysfunction of Alzheimer's disease through regulating the mTOR signaling pathway","volume":"20","author":"Kou","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib129","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1021\/acs.jmedchem.5b00586","article-title":"New frontiers in druggability","volume":"58","author":"Kozakov","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108081_bib130","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1177\/1352458515623365","article-title":"Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity","volume":"22","author":"Kuhle","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.neuropharm.2020.108081_bib131","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jfma.2015.04.001","article-title":"Current and novel therapeutic molecules and targets in Alzheimer's disease","volume":"115","author":"Kumar","year":"2016","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2020.108081_bib132","doi-asserted-by":"crossref","first-page":"W200","DOI":"10.1093\/nar\/gkv353","article-title":"FAF-Drugs3: a web server for compound property calculation and chemical library design","volume":"43","author":"Lagorce","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2020.108081_bib133","series-title":"Sixth International Stockholm\/Springfield Symposium Advances in Alzheimer Therapy","first-page":"96","article-title":"Regulation of beta-APP processing with cholinesterase inhibitors in neuronal cell lines","author":"Lahiri","year":"2000"},{"key":"10.1016\/j.neuropharm.2020.108081_bib134","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.neurobiolaging.2014.03.027","article-title":"Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology","volume":"35","author":"Laurent","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2020.108081_bib135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1124\/pr.117.014092","article-title":"Anti-inflammatory effects of omega-3 fatty acids in the brain: physiological mechanisms and relevance to pharmacology","volume":"70","author":"Lay\u00e9","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2020.108081_bib136","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-1-4939-2627-5_2","article-title":"Application of systems theory in longitudinal studies on the origin and progression of Alzheimer's disease","volume":"1303","author":"Lista","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib137","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jama.1997.03540340027028","article-title":"Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation","volume":"277","author":"Lopera","year":"1997","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2020.108081_bib138","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s12272-015-0640-5","article-title":"Role of computer-aided drug design in modern drug discovery","volume":"38","author":"Macalino","year":"2015","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.neuropharm.2020.108081_bib139","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1517\/17425255.2016.1168804","article-title":"ABC transporters at the blood-brain barrier","volume":"12","author":"Mahringer","year":"2016","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib140","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/ncb1007","article-title":"Crosstalk between Rap1 and Rac regulates secretion of sAPP\u03b1","volume":"5","author":"Maillet","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2018.00509","article-title":"Effects of physical exercise on cognitive functioning and wellbeing: biological and psychological benefits","volume":"9","author":"Mandolesi","year":"2018","journal-title":"Front. Psychol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib142","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.147","article-title":"1\u201342 \u03b2-Amyloid peptide requires PDK1\/nPKC\/Rac 1 pathway to induce neuronal death","volume":"3","author":"Manterola","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108081_bib143","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/00001756-200508010-00018","article-title":"Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity","volume":"16","author":"Marrazzo","year":"2005","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2020.108081_bib144","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neuropharm.2020.108081_bib145","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neuropharm.2020.108081_bib146","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108081_bib147","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","article-title":"The pharmacology of sigma-1 receptors","volume":"124","author":"Maurice","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108081_bib148","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0165-0173(95)00011-9","article-title":"The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases","volume":"21","author":"McGeer","year":"1995","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2020.108081_bib149","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib150","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nn.3718","article-title":"Whole-genome analyses of whole-brain data: working within an expanded search space","volume":"17","author":"Medland","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib151","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3233\/JAD-150897","article-title":"Cerebrospinal fluid markers of Alzheimer's disease pathology and microglial activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer's disease","volume":"50","author":"Melah","year":"2016","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib152","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","article-title":"Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the mayo clinic study on aging","volume":"74","author":"Mielke","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neuropharm.2020.108081_bib153","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib154","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1523\/JNEUROSCI.4098-07.2008","article-title":"A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging","volume":"28","author":"Miller","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib155","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-0404.2008.01086.x","article-title":"Long-term rivastigmine treatment in a routine clinical setting","volume":"119","author":"Minthon","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2020.108081_bib156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004597","article-title":"Distinctive behaviors of druggable proteins in cellular networks","volume":"11","author":"Mitsopoulos","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib157","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ijc.11669","article-title":"Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2","volume":"109","author":"Mizuarai","year":"2004","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.neuropharm.2020.108081_bib158","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0924-977X(99)80460-X","article-title":"Donepezil preserves functional status in Alzheimer's disease patients: results from a 1-year prospective placebo-controlled attrition study","volume":"9","author":"Mohs","year":"1999","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2020.108081_bib159","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","article-title":"Current state of Alzheimer's fluid biomarkers","volume":"136","author":"Molinuevo","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib160","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/ncomms2494","article-title":"Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease","volume":"4","author":"Moreno-Gonzalez","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2020.108081_bib161","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jalz.2019.03.007","article-title":"Annex: NIMA\u2013wellcome trust consortium for neuroimmunology of mood disorders and Alzheimer's disease. inflammatory biomarkers in Alzheimer's disease plasma","volume":"15","author":"Morgan","year":"2019","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.neuropharm.2020.108081_bib162","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/00001756-199503000-00012","article-title":"Cholinesterase inhibitors increase secretion of APPs in rat brain cortex","volume":"6","author":"Mori","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2020.108081_bib163","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076941","article-title":"Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival","volume":"8","author":"Mori","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.neuropharm.2020.108081_bib164","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00280-004-0931-x","article-title":"Single nucleotide polymorphisms modify the transporter activity of ABCG2","volume":"56","author":"Morisaki","year":"2005","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib165","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4155\/cli.12.93","article-title":"Developing an international network for Alzheimer's research: the dominantly inherited alzheimer network","volume":"2","author":"Morris","year":"2012","journal-title":"Clin. Invest."},{"key":"10.1016\/j.neuropharm.2020.108081_bib166","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2017.00278","article-title":"Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes","volume":"11","author":"Mustapic","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib167","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708763","article-title":"Amyloid blood biomarker detects Alzheimer's disease","volume":"10","author":"Nabers","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.neuropharm.2020.108081_bib168","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2020.108081_bib169","series-title":"Phase 2a dose finding","author":"Nct02244541","year":"2014"},{"key":"10.1016\/j.neuropharm.2020.108081_bib170","series-title":"An extension study of ANAVEX2-73 in patients with mild to moderate Alzheimer's disease","author":"Nct02756858","year":"2016"},{"key":"10.1016\/j.neuropharm.2020.108081_bib171","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","article-title":"A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial","volume":"385","author":"Ngandu","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108081_bib172","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fnins.2016.00265","article-title":"Drug design for CNS diseases: polypharmacological profiling of compounds using cheminformatic, 3D-QSAR and virtual screening methodologies","volume":"10","author":"Nikolic","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib173","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The \u201cArctic\u201d APP mutation (E693G) causes Alzheimer's disease by enhanced A\u03b2 protofibril formation","volume":"4","author":"Nilsberth","year":"2001","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib174","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1126\/science.1411529","article-title":"Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors","volume":"258","author":"Nitsch","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108081_bib175","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-019-1399-2","article-title":"Glial activation and inflammation along the Alzheimer's disease continuum","volume":"16","author":"Nordengen","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2020.108081_bib176","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/jamaneurol.2019.0845","article-title":"Blood biomarkers for use in alzheimer disease\u2014moving from \u201cif\u201d to \u201chow?","volume":"76","author":"O'Bryant","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib177","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13195-016-0208-8","article-title":"The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease","volume":"8","author":"\u00d6hrfelt","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2020.108081_bib178","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib179","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0197-0186(00)00091-7","article-title":"Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro","volume":"38","author":"Pakaski","year":"2001","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2020.108081_bib181","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for alzheimer disease\u2013related \u03b2-amyloid status","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neuropharm.2020.108081_bib182","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","article-title":"Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease","volume":"55","author":"Palop","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2020.108081_bib183","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrn.2016.141","article-title":"Network abnormalities and interneuron dysfunction in Alzheimer disease","volume":"17","author":"Palop","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib184","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awx120","article-title":"Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease","volume":"140","author":"Parbo","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108081_bib185","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/brain\/awy347","article-title":"Plasma tau\/amyloid-\u03b21\u201342 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease","volume":"142","author":"Park","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108081_bib186","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1478-811X-8-23","article-title":"Rac and Rho GTPases in cancer cell motility control","volume":"8","author":"Parri","year":"2010","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.neuropharm.2020.108081_bib187","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1093\/brain\/awt171","article-title":"Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology","volume":"136","author":"Perez-Nievas","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108081_bib188","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jns.2005.03.015","article-title":"Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss","volume":"233","author":"Petzold","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib189","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.bbi.2017.01.020","article-title":"Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults","volume":"62","author":"Popp","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2020.108081_bib190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2020.108081_bib191","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/13543784.2017.1364360","article-title":"Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease","volume":"26","author":"Prickaerts","year":"2017","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2020.108081_bib192","doi-asserted-by":"crossref","first-page":"17680","DOI":"10.1523\/JNEUROSCI.4740-11.2011","article-title":"Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults","volume":"31","author":"Putcha","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib193","first-page":"197","article-title":"Long-term cognitive benefit from Galantamine in Alzheimer's disease","volume":"1","author":"Rainer","year":"1998","journal-title":"Int. J. Geriatr. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib194","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1146\/annurev-pharmtox-011613-135943","article-title":"The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication","volume":"54","author":"Rask-Andersen","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib195","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JAD-2011-0059","article-title":"Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments","volume":"26","author":"Reiman","year":"2011","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib196","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1212\/01.wnl.0000271395.29695.9a","article-title":"Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study","volume":"69","author":"Reitz","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108081_bib197","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/jamapsychiatry.2015.1546","article-title":"Long-term risk of dementia in persons with schizophrenia: a Danish population-based cohort study","volume":"72","author":"Ribe","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108081_bib198","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1126\/science.1255905","article-title":"BRAIN NETWORKS. Correlated gene expression supports synchronous activity in brain networks","volume":"348","author":"Richiardi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108081_bib199","doi-asserted-by":"crossref","first-page":"44881","DOI":"10.1074\/jbc.M109008200","article-title":"The human serotonin 5-HT 4 receptor regulates secretion of non-amyloidogenic precursor protein","volume":"276","author":"Robert","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108081_bib200","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2174\/1570159X16666180412092859","article-title":"Nerve growth factor: early studies and recent clinical trials","volume":"16","author":"Rocco","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib201","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/brain\/awv404","article-title":"Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease","volume":"139","author":"Rodriguez-Vieitez","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2020.108081_bib202","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jalz.2018.01.008","article-title":"Principles for central nervous system inflammation research: a call for a consortium approach","volume":"14","author":"Rogers","year":"2018","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib203","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/0197-4580(96)00115-7","article-title":"Inflammation and Alzheimer's disease pathogenesis","volume":"17","author":"Rogers","year":"1996","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2020.108081_bib204","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0924-977X(97)00079-5","article-title":"Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study","volume":"8","author":"Rogers","year":"1998","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2020.108081_bib205","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.drudis.2017.03.014","article-title":"Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine","volume":"22","author":"Roukos","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2020.108081_bib206","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nm1206","article-title":"Somatostatin regulates brain amyloid \u03b2 peptide A\u03b242 through modulation of proteolytic degradation","volume":"11","author":"Saito","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2020.108081_bib207","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13195-018-0439-y","article-title":"Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease","volume":"10","author":"S\u00e1nchez-Valle","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2020.108081_bib208","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11910-004-0084-7","article-title":"Cognitive reserve: implications for diagnosis and prevention of Alzheimer's disease","volume":"4","author":"Scarmeas","year":"2004","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108081_bib209","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1083\/jcb.74.1.241","article-title":"Immunofluorescence studies of neurofilaments in the rat and human peripheral and central nervous system","volume":"74","author":"Schlaepfer","year":"1977","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.14283\/jpad.2017.23","article-title":"Effects of omega-3 fatty acids on resting cerebral perfusion in patients with mild cognitive impairment: a randomized controlled trial","volume":"5","author":"Schwarz","year":"2018","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib211","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuron.2009.03.024","article-title":"Neurodegenerative diseases target large-scale human brain networks","volume":"62","author":"Seeley","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2020.108081_bib212","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JAD-181152","article-title":"Cerebrospinal fluid and plasma biomarkers in neurodegenerative diseases","volume":"68","author":"Seino","year":"2019","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib213","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00005072-199409000-00003","article-title":"Alzheimer's disease: a central role for amyloid","volume":"53","author":"Selkoe","year":"1994","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib214","article-title":"An antidepressant decreases CSF A production in healthy individuals and in transgenic AD mice","volume":"6","author":"Sheline","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2020.108081_bib215","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41593-018-0312-0","article-title":"Human cognition involves the dynamic integration of neural activity and neuromodulatory systems","volume":"22","author":"Shine","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib216","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","article-title":"CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival","volume":"83","author":"Skillback","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108081_bib217","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1146\/annurev.immunol.17.1.905","article-title":"The wiskott-aldrich syndrome protein (wasp): roles in signaling and cytoskeletal organization","volume":"17","author":"Snapper","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib218","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19336896.2017.1405207","article-title":"Somatostatin in Alzheimer's disease: a new role for an old player","volume":"12","author":"Solarski","year":"2018","journal-title":"Prion"},{"key":"10.1016\/j.neuropharm.2020.108081_bib219","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40035-016-0053-5","article-title":"miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer's disease and other types of dementia \u2013 an exploratory study","volume":"5","author":"S\u00f8rensen","year":"2016","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.neuropharm.2020.108081_bib220","article-title":"A mathematical model of multisite phosphorylation of tau protein","volume":"13","author":"Stepanov","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.neuropharm.2020.108081_bib221","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","article-title":"Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease","volume":"14","author":"Sutphen","year":"2018","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib222","doi-asserted-by":"crossref","first-page":"172743","DOI":"10.1016\/j.pbb.2019.172743","article-title":"Diet and Alzheimer's dementia \u2013 nutritional approach to modulate inflammation","volume":"184","author":"Szczechowiak","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.108081_bib223","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jalz.2018.06.3058","article-title":"A systems-based model of Alzheimer's disease","volume":"15","author":"Tang","year":"2019","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib224","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00642","article-title":"Basal forebrain volume, but not hippocampal volume, is a predictor of global cognitive decline in patients with Alzheimer's disease treated with cholinesterase inhibitors","volume":"9","author":"Teipel","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib225","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.3233\/JAD-170784","article-title":"Plasma amyloid-\u03b2 (A\u03b242) correlates with cerebrospinal fluid A\u03b242 in Alzheimer's disease","volume":"62","author":"Teunissen","year":"2018","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib226","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","article-title":"Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease","volume":"1362","author":"Thorsell","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108081_bib227","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00693","article-title":"Fluoxetine and vortioxetine reverse depressive-like phenotype and memory deficits induced by a\u03b21-42 oligomers in mice: a key role of transforming growth factor-\u03b21","volume":"10","author":"Torrisi","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib228","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neurobiolaging.2019.08.032","article-title":"Biomarker-guided clustering of Alzheimer's disease clinical syndromes","volume":"83","author":"Toschi","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2020.108081_bib229","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.pneurobio.2011.07.004","article-title":"Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention","volume":"95","author":"Trojanowski","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib230","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/2191-219X-2-57","article-title":"Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene","volume":"2","author":"van Assema","year":"2012","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.neuropharm.2020.108081_bib231","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(16)30950-3","article-title":"Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial","volume":"388","author":"van Charante","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2020.108081_bib232","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081004","article-title":"Development of NMDAR antagonists with reduced neurotoxic side effects: a study on GK11","volume":"8","author":"Vandame","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.neuropharm.2020.108081_bib233","first-page":"58","article-title":"Antioxidants in the diet and cognitive function: which role for the mediterranean life-style?","volume":"4","author":"Vassalle","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib234","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/jsfa.6473","article-title":"Effect of flavonoids on learning, memory and neurocognitive performance: relevance and potential implications for Alzheimer's disease pathophysiology","volume":"94","author":"Vauzour","year":"2014","journal-title":"J. Sci. Food Agric."},{"key":"10.1016\/j.neuropharm.2020.108081_bib235","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuint.2015.08.004","article-title":"Neuroinflammatory processes in cognitive disorders: is there a role for flavonoids and n-3 polyunsaturated fatty acids in counteracting their detrimental effects?","volume":"89","author":"Vauzour","year":"2015","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2020.108081_bib236","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.febslet.2008.04.039","article-title":"Rho GTPases in cancer cell biology","volume":"582","author":"Vega","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2020.108081_bib237","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.jalz.2018.06.3053","article-title":"Association of cerebrospinal fluid \u03b1-synuclein with total and phospho-tau(181) protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers","volume":"14","author":"Vergallo","year":"2018","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2020.108081_bib238","series-title":"Oxford Textbook of Old Age Psychiatry","article-title":"Chapter 6. Biomarkers for Alzheimer's disease","author":"Vergallo","year":"2019"},{"key":"10.1016\/j.neuropharm.2020.108081_bib239","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jalz.2019.03.009","article-title":"Plasma amyloid \u03b2 40\/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease","volume":"15","author":"Vergallo","year":"2019","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.neuropharm.2020.108081_bib240","article-title":"Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting","volume":"565","author":"Wallin","year":"2011","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2020.108081_bib241","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000098052","article-title":"Donepezil in Alzheimer's disease: what to expect after 3 Years of treatment in a routine clinical setting","volume":"23","author":"Wallin","year":"2007","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"10.1016\/j.neuropharm.2020.108081_bib242","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000079201","article-title":"Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy","volume":"18","author":"Wallin","year":"2004","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"10.1016\/j.neuropharm.2020.108081_bib243","doi-asserted-by":"crossref","first-page":"14423","DOI":"10.1038\/s41598-017-13759-5","article-title":"Alzheimer's disease and cigarette smoke components: effects of nicotine, PAHs, and Cd(II), Cr(III), Pb(II), Pb(IV) ions on amyloid-\u03b2 peptide aggregation","volume":"7","author":"Wallin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108081_bib244","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid \u03b2 protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2020.108081_bib245","article-title":"MicroRNAs in Alzheimer's disease","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.neuropharm.2020.108081_bib246","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000437050","article-title":"Longitudinal associations between survival in Alzheimer's disease and cholinesterase inhibitor use, progression, and community-based services","volume":"40","author":"Wattmo","year":"2015","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"10.1016\/j.neuropharm.2020.108081_bib247","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/alzrt85","article-title":"Predictors of long-term cognitive outcome in Alzheimer's disease","volume":"3","author":"Wattmo","year":"2011","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2020.108081_bib248","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/WAD.0b013e3181f5dd97","article-title":"Long-term outcome and prediction models of activities of daily living in alzheimer disease with cholinesterase inhibitor treatment","volume":"25","author":"Wattmo","year":"2011","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuropharm.2020.108081_bib249","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1523\/JNEUROSCI.1230-11.2011","article-title":"Increased hippocampal default mode synchronization during rest in middle-aged and elderly APOE 4 carriers: relationships with memory performance","volume":"31","author":"Westlye","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib250","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13195-019-0472-5","article-title":"Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease","volume":"11","author":"Weston","year":"2019","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2020.108081_bib251","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","article-title":"Serum neurofilament light in familial Alzheimer disease","volume":"89","author":"Weston","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108081_bib252","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.169","article-title":"BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology","volume":"7","author":"Wilson","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108081_bib253","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer's disease and other dementias: a priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib254","series-title":"Twelfth Annual Congress of the European College of Neuropsychopharmacology","first-page":"30","article-title":"Donepezil enhances global function, cognition and activities of daily living compared with placebo one year","author":"Winblad","year":"1999"},{"key":"10.1016\/j.neuropharm.2020.108081_bib255","doi-asserted-by":"crossref","first-page":"36626","DOI":"10.1038\/srep36626","article-title":"Network motifs modulate druggability of cellular targets","volume":"6","author":"Wu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2020.108081_bib256","first-page":"94","article-title":"Identification OF discriminative imaging proteomics associations IN ALZHEIMER'S disease via a novel sparse correlation model","volume":"22","author":"Yan","year":"2017","journal-title":"Pac. Symp. Biocomput."},{"key":"10.1016\/j.neuropharm.2020.108081_bib257","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3233\/JAD-170810","article-title":"Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer's disease","volume":"61","author":"Yang","year":"2018","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2020.108081_bib258","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","article-title":"Association of cerebrospinal fluid neurofilament light concentration with alzheimer disease progression","volume":"73","author":"Zetterberg","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neuropharm.2020.108081_bib259","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer's disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuropharm.2020.108081_bib260","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","article-title":"Dysfunction of NMDA receptors in Alzheimer's disease","volume":"37","author":"Zhang","year":"2016","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib261","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-pharmtox-010611-134520","article-title":"Systems pharmacology: network analysis to identify multiscale mechanisms of drug action","volume":"52","author":"Zhao","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2020.108081_bib262","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2016.00059","article-title":"Anti-microRNAs as novel therapeutic agents in the clinical management of Alzheimer's disease","volume":"10","author":"Zhao","year":"2016","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib263","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2016.00140","article-title":"Over-expressed pathogenic miRNAs in Alzheimer's disease (AD) and prion disease (PrD) drive deficits in TREM2-mediated A\u03b242 peptide clearance","volume":"8","author":"Zhao","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib264","doi-asserted-by":"crossref","first-page":"30105","DOI":"10.3390\/ijms161226223","article-title":"MicroRNA (miRNA) signaling in the human CNS in sporadic Alzheimer's disease (AD)-Novel and unique pathological features","volume":"16","author":"Zhao","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108081_bib265","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.tips.2013.08.004","article-title":"Computational methods for drug design and discovery: focus on China","volume":"34","author":"Zheng","year":"2013","journal-title":"Trends Pharmacol. Sci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820301490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820301490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:10:14Z","timestamp":1758438614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820301490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":265,"alternative-id":["S0028390820301490"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108081","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108081"}}